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Tuberculosis was declared a global emergency by theWorld Health Organization (WHO) in 1993. Following the
declaration and the promotion in 1995 of directly observed treatment short course (DOTS), a cost-effective
strategy to contain the tuberculosis epidemic, nearly 7 million lives have been saved compared with the pre-
DOTS era, high cure rates have been achieved in most countries worldwide, and the global incidence of
tuberculosis has been in a slow decline since the early 2000s. However, the emergence and spread of multidrug-
resistant (MDR) tuberculosis, extensively drug-resistant (XDR) tuberculosis, and more recently, totally drug-
resistant tuberculosis pose a threat to global tuberculosis control. Multidrug-resistant tuberculosis is a man-made
problem. Laboratory facilities for drug susceptibility testing are inadequate in most tuberculosis-endemic
countries, especially in Africa; thus diagnosis is missed, routine surveillance is not implemented, and the actual
numbers of global drug-resistant tuberculosis cases have yet to be estimated. This exposes an ominous situation
and reveals an urgent need for commitment by national programs to health system improvement because the
response to MDR tuberculosis requires strong health services in general. Multidrug-resistant tuberculosis and
XDR tuberculosis greatly complicate patient management within resource-poor national tuberculosis
programs, reducing treatment efficacy and increasing the cost of treatment to the extent that it could
bankrupt healthcare financing in tuberculosis-endemic areas. Why, despite nearly 20 years of WHO-promoted
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activity and .12 years of MDR tuberculosis–specific activity, has the country response to the drug-resistant tuberculosis
epidemic been so ineffectual? The current dilemmas, unanswered questions, operational issues, challenges, and priority needs
for global drug resistance screening and surveillance, improved treatment regimens, and management of outcomes and
prevention of DR tuberculosis are discussed.
The World Health Organization (WHO) is the directing and
coordinating authority on international health within the
United Nations system. Through WHO’s policies and support,
governments can tackle global health problems and improve
people’s well-being. It was almost 2 decades ago that WHO
declared tuberculosis to be a global emergency and launched
the cost-effective global tuberculosis control strategy named
directly observed treatment short course (DOTS) [1, 2]. In 1999,
with the growing threat of drug-resistant (DR) tuberculosis,
WHO decided to tackle it through a complementary approach
focused on provisions for treating multidrug-resistant (MDR)
tuberculosis [3]. In 2000, recognizing that the cost and poor
availability of high-quality drugs were barriers to successful
implementation of a programmatic management of MDR tu-
berculosis, WHO, together with some other agencies, set up the
Green Light Committee (GLC) to help countries gain access to
affordable, high-quality second-line drugs [4]. In 2002, ac-
knowledging that a critical lack of tuberculosis laboratory
services capacity was a barrier to effective tuberculosis care, the
DOTS Expansion Working Group of the Stop TB Partnership
established a subgroup on laboratory capacity strengthening
(now the Global Laboratory Initiative), hosted by WHO, to
address this. These leadership initiatives coincided with an
era of unprecedented funding for global tuberculosis control
activities through organizations such as The Global Fund.
The slow decline in tuberculosis incidence observed in the
past few years is encouraging, but there remains a great need
to enhance control efforts because the global burden of tuber-
culosis remains very high and control efforts have been dogged
by the emergence of DR strains of Mycobacterium tuberculosis.
WHO estimates that approximately 640 000 cases were due to
MDR tuberculosis in 2008 [5]. Multidrug-resistant tuberculosis
is a man-made problem, resulting from improper use of anti-
tuberculosis drugs and likely the substandard quality of tuber-
culosis drugs used in certain settings. The identification and
spread of MDR tuberculosis, extensively drug-resistant (XDR)
tuberculosis , and more recently, totally drug-resistant (TDR)
tuberculosis pose a major threat to global tuberculosis control.
Of the estimated 290 000 cases of MDR tuberculosis that could
be diagnosed if all notified tuberculosis cases were drug sus-
ceptibility tested, only 10% were reported to be enrolled in
treatment for MDR tuberculosis, and a much smaller percentage
received treatment from programs that use drugs approved by
the GLC [6]. In the 27 high-burden, MDR tuberculosis coun-
tries, only 1% of new tuberculosis cases and 3% of previously
treated cases are screened for DR tuberculosis by a laboratory.
The occurrence of MDR tuberculosis and XDR tuberculosis
greatly complicates patient management within resource-poor
national tuberculosis programs, reducing treatment efficacy
and increasing the cost of treatment to the extent that it
could bankrupt healthcare systems in tuberculosis-endemic
areas. Multidrug-resistant tuberculosis has great potential to
bankrupt patients because of the more complicated, lengthy
therapy involved [7–9] and the inability of these patient to
work.
A serious question arises: Why, despite nearly 20 years of
WHO-promoted activities in tuberculosis control and .12 years
of MDR tuberculosis–specific activity, has the global response
to the DR tuberculosis epidemic been so slow and ineffectual?
In this article, we discuss current dilemmas, unanswered ques-
tions, operational issues, challenges, and priority needs for
global drug resistance screening and surveillance, improved
treatment regimens and management of outcomes in human
immunodeficiency virus (HIV)–infected and uninfected adults
and children, and infection control and prevention of DR
tuberculosis.
DEFINITIONS, THEIR USEFULNESS, AND THEIR
LIMITATIONS
Current definitions of DR tuberculosis are as follows: MDR
tuberculosis is defined as resistance to the 2 key first-line anti-
tuberculosis drugs, isoniazid (INH) and rifampicin (RIF). The
term XDR tuberculosis appeared in the literature for the first
time in March 2006 in a report jointly published by WHO
and the Centers for Disease Control and Prevention (CDC);
later in the same year an outbreak of XDR tuberculosis as-
sociated with high mortality rates occurred among HIV-
infected patients treated at a rural hospital in Tugela Ferry,
South Africa [10]. It is presently defined as tuberculosis caused
by M. tuberculosis strains that are resistant to at least INH
and RIF (ie, MDR tuberculosis) plus any fluoroquinolone and
at least 1 of 3 injectable anti-tuberculosis drugsdcapreomycin,
kanamycin, or amikacin. Totally drug-resistant tuberculosis is
defined as tuberculosis caused by M. tuberculosis strains re-
sistant to all first- and second-line licensed anti-tuberculosis
drugs. Surveys of DR tuberculosis based on these definitions
can be useful markers of efficiency and quality of national,
regional, or global tuberculosis control programs and can
be used as powerful advocacy tools for evoking political and
community support. Furthermore, because treatment of DR
tuberculosis is more costly, data on drug resistance can inform
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health system budgetary planning. Identification of distinct
groups of patients with MDR tuberculosis and XDR tuber-
culosis are important in clinical trials assessing the efficacy
and duration of newer drugs or drug regimens. However,
the current broad-based definition of MDR tuberculosis and
XDR tuberculosis may not be sufficient to effectively ran-
domize patient groups in clinical trials and may require subclasses
of these groups based on actual drug resistance patterns to be
studied.
The complexities of phenotypic mycobacterial drug suscep-
tibility testing and the molecular mechanisms of M. tuberculosis
drug resistance and cross-resistance [11] can make these defi-
nitions imprecise and confusing because drug concentrations
used in definitions of drug resistance are not the same as drug
concentrations achieved at the site of infection in vivo. Fur-
thermore, the extent of resistance and cross-resistance conferred
by distinct mutations differs substantially for INH, RIF, ami-
noglycosides, and fluoroquinolones [12]. Although necessary
for treatment guidance, such complex diagnoses can only be
made in a few quality-controlled tuberculosis reference labo-
ratories, generally in developed countries where the burden of
disease is lowest.
GLOBAL EPIDEMIOLOGICAL DATA AND
ESTIMATES OF DRUG-RESISTANT
TUBERCULOSIS
Drug-resistant strains of M. tuberculosis are globally dispersed,
although the true scale of the threat remains undefined. Drug
resistance surveillance data were patchy and often unreliable
because of poorly standardized methodologies and biased
patient selection, with the highest uncertainty in tuberculosis-
endemic areas with limited resources where resistance testing
is often not available. In a literature review of data published
between 1985 and 1994, the authors found that rates varied
widely between settings [13]. In 1994, WHO and the Interna-
tional Union Against Tuberculosis and Lung Diseases established
a Global Surveillance Project to collect and assess data on the
extent and type of anti-tuberculosis drug resistance and to
monitor trends over time. Guidelines for surveillance of drug
resistance were published, and a network of reference centers
was established to aid standardization of procedures. The most
recent report published in 2010 revealed that no high-burden
country undertakes continuous surveillance, and although some
countries undertake periodic surveys, only 47 countries have
performed national surveys for drug resistance within the last
decade [6]. World Health Organization estimates state that
3.6% of global tuberculosis cases (440 000 cases) were due to
MDR tuberculosis in 2008, but these estimates are rather
crude (Figure 1). The lack of laboratory capacity to test for
drug resistance in much of Africa, Eastern Europe, and Asia
makes it nearly impossible to accurately assess the situation,
and the true global burden of DR tuberculosis may be higher
than current estimates (Tables 1 and 2).
The large number of MDR tuberculosis cases reported from
Eastern Europe and South Africa may only be the tip of the
iceberg, although countries with limited or no access to second-
line anti-tuberculosis drugs would not be expected to have
a significant ‘‘home-grown’’ XDR tuberculosis problem, although
immigration of patients from other countries is a potential
source. The practice of reporting the prevalence of drug re-
sistance as the proportion of cases with MDR tuberculosis is
a further source of confusion regarding the global burden of
drug resistance. Although a useful measure of the effectiveness
of treatment, it does not indicate the absolute burden of MDR
tuberculosis. For example, although the burden of MDR tu-
berculosis in South Africa appears low compared with that of
Eastern European countries (when expressed as a proportion
of the total tuberculosis caseload), the absolute number of cases
is in reality very high because South Africa has the third
highest tuberculosis caseload in the world [6, 14]. Similarly
the absolute numbers of cases in India and China are very
large, although as a proportion of total tuberculosis cases, the
burden seems relatively small.
Mechanisms of drug resistance in M. tuberculosis originate
either from spontaneous chromosomal mutations at low
frequency (primary drug resistance) or from misuse of anti-
tuberculosis drugs by physicians and patients, which leads
to monotherapy or intermittent drug intake (secondary drug
resistance) [11]. Secondary drug resistance is extremely rare
in patients who adhere to their prescribed anti-tuberculosis
regimen. Differentiation of drug-resistant cases is made for
programmatic reasons in which incident cases arising from
a transmission event are distinguished from those in which
resistance has emerged during the course of an infection
through inadequate therapy. WHO reports resistance in ‘‘pre-
viously treated cases’’ (defined as those who have received at
least 1 month of treatment with anti-tuberculosis drugs),
and resistance in ‘‘new cases’’ (defined as a newly registered
episode of DR tuberculosis in a patient who, in response to
direct questioning, denies having had any prior anti-tuberculosis
treatment for more than 1 month, and, in countries where
adequate documentation is available, patients for whom there
is no evidence of such history) [6]. Of 12 686 confirmed new
MDR tuberculosis cases reported worldwide in 2010, 11 646
were reported in the European region, the vast majority of
which were from Eastern Europe. A total of 22 875 confirmed
previously treated cases were reported to WHO in 2010, the
majority of which again were from Eastern Europe [15]. The
highest proportions of new and previously treated forms of
MDR tuberculosis are found in Eastern Europe and Central
Asia, with Azerbaijan, for example, reporting 22.3% and 55.8%
MDR tuberculosis in new and previously treated tuberculosis
cases, respectively [6]. The proportion of MDR tuberculosis
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is always higher in previously treated tuberculosis cases than
in new cases. India and China collectively accounted for almost
half of the global cases of MDR tuberculosis in 2010, reporting
high proportions of MDR tuberculosis in previously treated
cases (17.2% and 25.6%, respectively) but relatively small
proportions in new cases (2.3% and 5.7%, respectively) [15]. It
was assumed that the incidence of MDR tuberculosis in new
cases was an indicator of levels of transmission. However,
genotyping studies have revealed the possibility of secondary
infection, in which tuberculosis patients with drug-susceptible
tuberculosis are infected with a new MDR M. tuberculosis
strain, and thus an alternative measure of transmission is
required to avoid underestimation of the problem.
DIAGNOSIS OF DRUG-RESISTANT
TUBERCULOSIS
Sputum microscopy remains the most widely used diagnostic
test and is frequently the only test available in tuberculosis-
endemic areas. Although it allows detection of the most
infectious cases, it is not a sensitive test and case detection rates
remain low in developing countries [16]. In the WHO African
Region, less than half of the estimated incident tuberculosis
Table 1. Limitations of AvailableMultidrug-Resistant Tuberculosis
Data
Poor diagnostic, surveillance, and reporting systems for
drug-resistant tuberculosis in most developing countries due to
lack of resources and expertise.
Many tuberculosis-endemic areas are completely data deficient.
Continued surveillance occurs mainly in developed countries.
Periodic survey data are mostly old and outdated, although
a number of surveys are currently under way.
The proportion of drug-resistant cases among new tuberculosis
patients reflects transmitted disease, although retreatment
cases probably represent a mix of transmitted (primary) and
acquired (secondary) resistance.
Numbers of human immunodeficiency virus–infected patients with
drug-resistant tuberculosis are poorly quantified.
No reliable pediatric data on multidrug-resistant tuberculosis and
extensively drug-resistant tuberculosis exist.
Figure 1. A, Estimated absolute number of multidrug resistance (MDR) among tuberuculosis (TB) cases, 2009. B, Proportions of MDR among new
tuberculosis cases, 1994–2010.
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cases each year are detected and notified [15]. Microscopy
cannot differentiate drug-susceptible tuberculosis from DR
tuberculosis. Drug susceptibility can be determined phenotypi-
cally by culture of M. tuberculosis isolates in the presence of
the drug or genotypically via detection of mutations within the
genome of M. tuberculosis that are known to confer resistance
to specific anti-tuberculosis drugs. Culture-based methods are
generally costly and time consuming and require a well-
functioning, biosecure laboratory. Alternative lower-cost, more
rapid culture-based methods, such as the microscopically ob-
served drug susceptibility assay and the nitrate reductase assay,
have also been endorsed for use by WHO, and a further rapid
culture method, thin-layer agar culture, is also undergoing
evaluation [17]. However, biosafety issues remain a stumbling
block to more widespread implementation of these assays.
Moreover, the technical infrastructure and expertise required
means that in practice such assays remain largely confined
to centralized reference laboratories. Access to such facilities
is very poor in most high-burden countries, and not only do
we fail to detect many tuberculosis patients, but also only a tiny
proportion of those that are diagnosed are tested for drug
resistance.
Rapid diagnosis is of paramount importance to improve
patient outcomes and limit ongoing transmission. During the
outbreak of MDR tuberculosis and XDR tuberculosis in rural
KwaZulu Natal Province in South Africa in 2006, it was
striking that many patients died during the period that sputum
samples were obtained and the diagnosis was finally made [10].
Such delays in diagnosis allow clonal spread of drug resistant
M. tuberculosis strains within vulnerable communities. Nucleic
acid amplification tests (NAATs) provide a means for signifi-
cantly more rapid detection of drug-resistant mutations, but
it is important to note that other factors also contribute to
resistance phenotype [18]. For some anti-tuberculosis drugs,
genotypic drug susceptibility testing is complex, with multiple
areas of the genome involved. Testing for large numbers of
mutations is technically challenging and beyond the scope of
real-time polymerase chain reaction (PCR) or line probe
technology. Following the report of the South African XDR
tuberculosis outbreak in 2008, WHO endorsed the use of line
Table 2. Challenges for Global Control of the Drug-Resistant Tuberculosis Epidemic
Diagnostic dilemma Microscopy-based diagnostics are unable to identify drug-resistant disease.
Phenotypic diagnosis is most accurate, but requires a P3 lab and is costly and time consuming.
Genotypic diagnosis offers rapid turnaround and fair accuracy; huge chance of false-positive
diagnosis.
Xpert MTB/RIF assay and false positives.
Infection control difficulties Containment of aerosol transmission in healthcare facilities and transmission hot-spots within
the community is difficult.
Early diagnosis and effective treatment of infectious cases are essential, but even if this is
achieved, treatment response is often slow.
Prolonged isolation of infectious patients is costly and poses multiple legal and ethical dilemmas.
Complicated treatment Second-line treatment is very expensive and is less potent and more toxic than first-line options.
Treatment duration is for a minimum of 2 years with a combination of multiple drugs; adherence
is a major challenge.
Optimal drug regimens are poorly characterized, and no fixed-dose combination tablets are in
existence.
Drug-resistant tuberculosis and
HIV coinfection issues
The HIV epidemic has greatly increased the burden on tuberculosis programs, undermining
treatment outcomes and fueling high rates of recurrent disease.
Expansion of HIV care and treatment settings is very vulnerable to transmission and outbreaks
of drug-resistant tuberculosis, affecting patients and healthcare workers.
Second-line tuberculosis drugs and antiretroviral drugs have many shared toxicities, and
patients with drug-resistant tuberculosis may be more susceptible to tuberculosis-immune
reconstitution disease.
Limited international and domestic funding Controlling the drug-resistant tuberculosis epidemic requires major investment.
Most countries simply cannot afford or maintain the sophisticated infrastructure required to
manage these patients in an optimal fashion.
People with drug-resistant tuberculosis are usually poor and marginalized with little financial or
political influence.
Lack of political commitment Lack of awareness in general; no ‘‘disease face.’’
Inaccurate numbers and poor quantification of the true disease burden.
No immediate threat perceived; no easy/cheap answers.
No international political pressure.
Abbreviation: HIV, human immunodeficiency virus.
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probe assays in resource-limited settings for the rapid molec-
ular detection of drug resistance in smear-positive specimens
or culture isolates [19].
DEVELOPMENT OF NEWER ASSAYS FOR
DETECTING DRUG RESISTANCE
In 2009, the GenoType MTBDRsl (Hain Lifescience) assay,
which is able to detect resistance to fluoroquinolones, amino-
glycosides, and ethambutol in culture isolates or smear-positive
sputum specimens, became available [20]. A WHO expert com-
mittee reviewed the evaluation data for second-line drug
susceptibility testing using the GenoType MTBDRsl test in
2010 but did not endorse it due to lack of sufficient evidence
on its accuracy. When used in combination with the GenoType
MTBDRplus assay, the GenoType MTBDRsl assay provides
a means of rapid detection of XDR tuberculosis. Using such
molecular assays reduces the time to diagnosis of MDR tuber-
culosis and XDR tuberculosis from weeks or months to a matter
of days.
A further major step forward has occurred with the de-
velopment of the Xpert MTB/RIF assay, a simplified NAAT
that can be used outside the domain of reference laboratories
in peripheral healthcare facilities [21]. This assay uses a series
of molecular probes and real-time PCR technology to detect
M. tuberculosis and the rpoB gene RIF resistance–associated
mutations [22]. The cartridge-based system requires minimal
laboratory expertise, and results are available in ,2 hours,
permitting a specific tuberculosis diagnosis and rapid detection
of RIF resistance. A large multicountry evaluation found excel-
lent performance characteristics [23], and an implementation
study found that this technology could be used successfully
at the district level, greatly reducing the time to tuberculosis
diagnosis and showing high sensitivity for rapid detection of
RIF resistance [24]. Further studies, however, have highlighted
a problem with false-positive RIF resistance results [24, 25], and
corrective measures are being instituted, including revisions
to the diagnostic platform software and redesign of one of the
assay oligonucleotide probes [22]. Thus, following detection
of an RIF-resistant strain, WHO recommends further testing
with another method to confirm RIF resistance and to assess
susceptibility to other agents [21]. More details of this assay are
outlined in McNerney et al’s article (this issue) on tuberculosis
diagnostics and biomarkers.
PATTERNS OF DRUG RESISTANCE
Single-drug (mono) resistance occurs commonly to INH.
Historical studies demonstrated a high risk of acquiring INH
resistance when tuberculosis patients with high bacillary loads
were treated with INH monotherapy. The widespread use of
INH preventive therapy (IPT) may fuel the emergence of INH
monoresistance, which is usually the first step toward MDR
tuberculosis if active tuberculosis disease is not adequately ruled
out prior to IPT initiation. However, the available evidence
suggests that the risk posed by IPT programs is less than an-
ticipated, and the standard 4-drug treatment seems adequate
even for those who fail IPT [26]. Rifampicin monoresistance
used to be uncommon but seems to be increasing in frequency.
This may be a false observation that reflects the increased sen-
sitivity of genetic tests to detect RIF resistance compared with
INH resistance. However, upward trends have been observed
using phenotypic results as well in areas where poor quality of
fixed-dose combination tablets have been used in the past. Rates
of resistance may be affected by changes in treatment patterns,
as some countries have only recently initiated RIF in the con-
tinuation phase of treatment. It is important to point out that
the Xpert MTB/RIF assay only detects RIF resistance, which
is often used as a surrogate for MDR tuberculosis. The failure
to detect INH monoresistance is a significant limitation of the
Xpert MTB/RIF assay. This poses 2 problems: (1) RIF or INH
monoresistance would not be recognized, and (2) widespread
usage will result in lower diagnosis of INH monoresistance.
Furthermore, there have been particular challenges with the
stability of some rpoB gene probes leading to false-positive RIF
resistance results. This is a major concern because incorrect
multidrug resistance identification would deprive these pa-
tients of optimal first-line therapy, which is more potent and
less toxic and costs a fraction of the price of MDR tuberculosis
treatment. Suggestions that these patients should not be started
on an expanded first-line regimen until phenotypic confirmation
of the actual drug susceptibility pattern are tempered by labo-
ratory evidence that RIF induces efflux pump activation that
significantly reduces flouroquinolone drug levels during co-
treatment [27]. Resistance to other first-line drugs, pyrazinamide
and ethambutol, are rarely tested for but seems to occur fre-
quently among MDR tuberculosis cases. This is not unexpected
in settings where first-line treatment often continues for months
until treatment failure is recognized, and even the use of re-
treatment regimens that include streptomycin as a fifth agent
offers poor protection against amplification of drug resistance.
MANAGEMENT OF DRUG-RESISTANT
TUBERCULOSIS
It is estimated that ,7% of MDR tuberculosis cases are diag-
nosed worldwide [6], and of these only 1% of patients receive
treatment from programs that use quality-assured anti-
tuberculosis drugs approved by the GLC. The GLC was set
up to monitor tuberculosis program performance and re-
strict the availability of second-line anti-tuberculosis drugs,
making them available only to countries that meet minimum
performance targets. Whereas WHO and the GLC focus their
attention on the public sector and national control programs,
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the private sector is not regulated in most countries. Individuals
with suspected MDR tuberculosis who cannot access second-
line treatment in the public sector may turn to private pro-
viders, who may supply drugs, but of variable quality and
without appropriate medical supervision, and thus the risks
of amplified resistance or the emergence of XDR tuberculosis
are high. Best practice guidelines need to be refined, taking
into account drug cost, the cost of missed diagnosis or initial
suboptimal treatment, side effects, and interactions with anti-
retrovirals. Although individualized regimens based on labo-
ratory drug susceptibility data remains the ideal, standardized
management algorithms based on local drug susceptibility
patterns seem the only pragmatic alternative to assist treat-
ment delivery at peripheral points of care. This should be
done as an integrated tuberculosis and HIV service, with strict
infection control measures.
COMPLEXITIES, DILEMMAS, AND PRIORITY
NEEDS FOR DRUG-RESISTANT TUBERCULOSIS
TREATMENT
Given that ,1% of MDR tuberculosis patients are estimated to
be on appropriate treatment [5, 28], massive treatment scale-up
is urgently required to reduce individual suffering and to avoid
ongoing transmission and a future scenario when DR tuber-
culosis strains cause the majority of tuberculosis cases [29].
Reasons for the lack of treatment scale-up include lack of
diagnostic capacity in countries with the highest burdens of
tuberculosis and DR tuberculosis, lack of political commitment,
and lack of the financial resources needed to reach universal
access for MDR tuberculosis treatment [30]. In addition, there
are complexities around supply and pricing of existing second-
line tuberculosis drugs, with ineffective global mechanisms
to ensure access to quality-assured and effective regimens to
treat MDR tuberculosis.
Early experience in the treatment of DR tuberculosis was
primarily gleaned from small, well-resourced programs, and
treatment was invariably individualized. Settings utilizing stan-
dardized or empiric treatment on a programmatic scale often
report poorer outcomes, resulting in treatment success in ap-
proximately 62% of cases [31, 32]. More recent evaluations
have reported higher success, up to 88% [33], but fundamental
biases, such as nonrandom differences in how treatment is
offered, influence the reported efficacy of regimens and also
potentially lead to erroneous conclusions. In general, outcomes
are suggested to be worse among HIV-infected individuals
[34, 35]. Disappointing treatment outcomes are largely explained
by the fact that treatment is lengthy and toxic, rendering ad-
herence extremely difficult for patients. Even with good patient
adherence, resistance amplification is common, resulting in
treatment failure and the creation of highly resistant tuberculosis
strains [36, 37].
Current recommendations for the treatment of DR tubercu-
losis are based on low-grade evidence. Randomized controlled
trials have not been conducted to the same degree that ulti-
mately led to the definition of the first-line tuberculosis regimen
currently used [38]. Instead, guidelines for the management
of MDR tuberculosis are based largely on expert opinion and
limited observational data, resulting in the recommended use
of drugs for which there is no or limited evidence of efficacy
[39, 40]. Implementation of these guidelines results in a wide
range of treatment regimens based on availability of drug
susceptibility testing, physician preference, and drug avail-
ability and cost in many settings. Such individualized treat-
ment approaches result in a modest improvement in outcomes
(64% treatment success vs 54% for standardized treatment in
meta-analyses) but no clear benefit in terms of mortality re-
duction (11% for both approaches) [32]. Clearly there is an
urgent need for defined DR tuberculosis regimens that are
shorter, more tolerable, and more effective and that have
undergone trials under programmatic conditions [33, 41].
Given this bleak picture, it is encouraging that there are
now several new promising compounds in the pipeline (see
Leinhardt et al in this issue). The most advanced of these are
TMC207 and OPC-67683, developed by Tibotec and Otsuka,
respectively [42–44]. Early data on TMC207 suggested a signifi-
cant negative interaction with RIF, a backbone first-line
drug, and hence efforts have been directed from the outset
toward DR tuberculosis treatment [45]. After promising phase
2 data, Tibotec has now approved the use of TMC207 under
compassionate-use criteria for patients with limited treatment
options. Due to poor treatment outcomes and high levels of
treatment failure and defaulting, there is considerable pressure
to make these drugs available sooner rather than later. Com-
passionate use can be seen as one way to speed up access to new
drugs for patients whose therapeutic options are few and who
therefore cannot afford to wait for the results of clinical trials.
However, care must be taken to ensure that compassionate use
does not result in inappropriate use and the early emergence of
resistance.
METHODOLOGICAL ISSUES IN
DRUG-RESISTANT TUBERCULOSIS
TREATMENT
In addition to debates on priorities for new and existing
tuberculosis drugs [46], there are important methodological
difficulties in conducting clinical trials for DR tuberculosis
(Table 3). The novel notion of the optimized background
regimen enables assessment of individual drug effects, but
it remains difficult to assess particular drug combinations in
clinical trials [39]. If a similar approach to clinical trials for
combinations of new and existing drugs with different dura-
tions is taken for DR tuberculosis, as was done for first-line
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treatment, there could be a delay of 20–30 years before a well-
evaluated regimen emerges [39]. Hence there is a need for
novel, innovative strategies to generate data that will inform
DR tuberculosis regimen development. Carefully guided pri-
oritization is required in order to test regimens most likely to
be efficacious, and importantly, able to be implemented under
routine conditions in decentralized, nonspecialized programs
in high-burden settings.
There have been some promising moves in this regard. The
TB Alliance, through the Critical Path to New TB Regimens,
has embarked on a series of early bactericidal activity (EBA)
trials testing novel combinations of drugs, which aim to con-
siderably reduce the time taken to develop full regimens [47].
There is debate in the tuberculosis clinical trial community
about the appropriateness of EBA for evaluation of new drug
combinations (see Phillips et al article in this issue). Further-
more, because the aim is to develop an entirely new regimen
for all tuberculosis (both drug susceptible and resistant) [48],
such a strategy will likely delay access to new drugs for DR
tuberculosis patients and will not take advantage of the potential
to combine new tuberculosis drugs with existing drugs cur-
rently used for DR tuberculosis. An entirely new tuberculosis
regimen will likely take many years to establish, and in the
meantime, DR tuberculosis will continue to exact an enormous
toll on mortality and further threaten tuberculosis control
efforts. Hence, there are strong arguments to concurrently
develop better regimens for DR tuberculosis. Another promising
approach is the use of individual patient-level meta-analyses
to better utilize existing observational data on DR tubercu-
losis treatment and outcomes. An analysis drawing data from
published meta-analyses aiming to assess drug choices and
duration of treatment is currently under way with full results
available soon [49]. This approach permits more extensive
analysis of treatment factors than conventional meta-analyses
but remains limited by the observational nature of the pri-
mary data and heterogeneity of treatment approaches.
SCALING UP DRUG-RESISTANT
TUBERCULOSIS TREATMENTdCONCERNS
AND DILEMMAS
Ultimately, if treatment is to be scaled up to the level required
to meet the hundreds of thousands of patients in need each year
and the millions currently waiting for treatment, some form
of standardization will inescapably be required in order to im-
prove access, reduce reliance on specialized services, and sim-
plify patient adherence. However, in the absence of a full drug
susceptibility profile, empiric regimens that take into account
prevailing resistance patterns and HIV prevalence in different
settings will be needed. With the expansion of case detection
promised by the introduction of rapid PCR-based diagnostics,
more programmatic data should be generated over the coming
years. The question arises as to how these data should be best
used to inform the design of clinical trials and advise national
programs on what drug regimens should be implemented.
One approach might be to draw on lessons learned from
other diseases with regard to combined databases and in-
formation sharing. In hematology, for example, a shared
database has been developed to draw data from multiple
sites. This approach has the advantage of standardizing data
collection, thus increasing the ability to undertake robust
statistical analyses. This has improved survival for pediatric
leukemia and increased the potential patient base for enrollment
in clinical trials [50].
Other approaches are needed to inform the conduct
of clinical trials that are most likely to result in usable,
Table 3. Methodological Difficulties and Possible Solutions to Identify Optimal Treatment Regimens for Drug-Resistant Tuberculosis
Methodological Difficulties Possible Solutions
Heterogeneous patient population; variable
drug resistance profiles
Testing novel drugs against an optimized background regimen (difficult to
assess particular drug combinations) tuberculosis
Little basic information regarding pharmacokinetics
and other drug characteristics
Use of individual patient-level meta-analyses to better utilize existing
observational data;expanded early bactericidal activity studies in patients
with drug-resistant tuberculosis
Risk of selection bias, especially with program-based
outcomes
Detailed pharmacokinetic and drug interaction studies for all
second-line drugs
Hundreds of possible combinations of existing and
new drugs and durations that could be tested
against specific resistance profiles
Validate surrogate marker of response to therapy (eg, 6-month culture
conversion rate)
Limited capacity to conduct large-scale trials in high
multidrug resistance–burden settings
Develop capacity within tuberculosis control programs to conduct
effectiveness trials of high quality
Length of time taken to achieve treatment success
and therefore assess efficacy
Using animal models to test multiple drug combinations for potential
synergy or antagonism, against infection with a variety of resistance
profiles
Need for novel, innovative strategies to generate data that
will inform drug-resistant tuberculosis regimen
development; carefully guided prioritization of human trials
Support novel drug development and testing against drug-resistant
strains
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efficacious regimens. This includes expanding efforts to develop
new models (mathematical, animal, and human) to direct
which drugs and which drug combinations should be taken
forward to trials and efforts to characterize markers of disease
progression and cure. In addition, various drug combinations
may have the potential to result in positive synergistic inter-
actions that may shorten treatment and increase efficacy. An
example of this is the potential synergistic effects of ethambutol
and pyrazinamide on clarithromycin [51, 52]. Unfortunately,
data on potential drug synergies is severely limited for existing
second-line tuberculosis drugs, mainly because many of these
drugs are not well characterized in terms of mechanisms of
action and pharmacokinetics [53]. Indeed, many currently used
second-line tuberculosis drugs are not even registered for long-
term use in tuberculosis treatment; the fluoroquinolones are
a notable example of this. There is also potential for novel
approaches to therapy, such as adjunctive therapy to limit tissue
damage, [54] and novel drug delivery mechanisms, such as in-
haled drugs [55]. Hence, in addition to novel methods of accu-
mulating observational data on outcomes, significantly more
targeted laboratory and pharmacokinetic studies are needed.
Encouragingly, there are several controlled trials under way
aiming to improve DR tuberculosis treatment (see details at
http://clinicaltrials.gov). Planning is also well advanced for
a clinical trial aiming to evaluate the successful 9-month regi-
men used in Bangladesh in other high MDR–burden settings
(STREAM study) [33, 56]. There are compelling reasons, both
humanitarian and epidemiological, to scale up access to the
best possible treatment for patients currently suffering from
DR tuberculosis. Questions remain as to whether the limited
global capacity for clinical trials in DR tuberculosis is being
optimally used. A more directed and informed strategy that
draws on the large range of mathematical and statistical tools
that are available to help support complex decision making
should be used to guide such decisions.
NEED FOR ANCILLARY OR ADJUNCT
TREATMENTS
The poor treatment outcomes for XDR tuberculosis and MDR
tuberculosis and the slow progress in development and evalua-
tion of new tuberculosis drugs now calls for evaluation of novel
adjunct therapies in addition to tuberculosis drug treatment.
A range of immune modulators have been considered for use
as adjunct treatment of DR tuberculosis [57]. These include
immunoregulatory approaches, immunosuppressive therapy, and
supplement effector cytokines. Immunoregulatory approaches,
which seek to alter the nature of the immune response, can be
divided into 3 subgroups: (1) those for which good manufacturing
practices (GMP) manufacturing capacity exists (high-dose IVIg;
HE2000-16a-bromoepiandrosterone; multidose heat-killed
Mycobacterium vaccae or Mycobacterium w; anti–interleukin 4);
(2) those for which GMP manufacturing capacity can be es-
tablished (DNA vaccine [HSP65]), and (3) the others (Dzherelo;
SCV-07 SciCLone; RUTI) [57]. Clinical trials with environ-
mental Mycobacterium species have not shown any benefit as
adjunct treatments. Trials with other preparations are hindered
by availability of funding and the high cost of the immuno-
therapeutic agent. A phase 1 study in patients in Belarus with
MDR tuberculosis and XDR tuberculosis is under way using
autologous bone marrow–derived mesenchymal stem cell trans-
fusions (M. Maeurer, personal oral communication, 2 December
2011) in an attempt to reinvigorate lung immune responses to
enhance mycobacterial clearance.
PREVENTION AND CONTROL MEASURES FOR
DRUG-RESISTANT TUBERCULOSISdIDEAL VS
REALITY
The existing BCG vaccine has played only a small role in pre-
venting the acquisition and spread of DR tuberculosis. New
effective vaccines against tuberculosis have the potential for
a significant and durable effect on reducing DR tuberculosis
globally. During the past decade, tuberculosis vaccine research
has developed a number of new vaccine candidates that are
under evaluation. Although the world eagerly awaits the results
of these trials, current emphasis must remain on basic pre-
vention and infection control measures. Pediatric data indicate
effective human-to-human transmission within households,
invalidating previous laboratory observations that drug-resistant
strains are likely to be less fit and thus pose a reduced trans-
mission risk [58]. The fitness cost associated with the acquisition
of drug resistance seems unpredictable as compensatory evolu-
tion has been demonstrated to account for improved fitness
of DR clinical strains with fitness approaching that of their
progenitor strains [59]. The spread of DR tuberculosis is omi-
nously linked to the HIV epidemic, as reflected by the clonal
nature of the XDR tuberculosis outbreak documented at Tugela
Ferry in KwaZulu Natal, South Africa [10], which showed that
person-to-person spread of DR tuberculosis can occur quickly
in hospitalized patients with HIV infection. Furthermore, all
grades of healthcare workers are at increased risk of acquiring
DR tuberculosis from patients because many hospitals in
resource-poor countries do not have appropriate facilities for
instituting infection control measures. There have been several
reports of XDR tuberculosis occurring in South African hos-
pital staff. This emphasizes the crucial importance of in-
stituting effective infection control measures within hospitals,
clinics, and confined institutions such as prisons, mines, and
other congregate settings.
Patients with DR tuberculosis should be managed as in-
patients in hospitals equipped with negative pressure isolation
facilities, appropriate masks for patients and staff, and admin-
istrative protocols to deal with such patients; appropriate
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environmental protective measures should also be taken. This
may not be feasible in most resource-poor settings. In warm
climates, adequate ventilation (.12 air changes per hour) ob-
tained by opening windows and doors is the most important
and easily implemented measure other than diagnosing and
treating infectious cases early and effectively and separating
suspected cases from high-risk patients, such as children and
HIV-infected individuals. Cough etiquette is also a cost-effective
intervention that needs to be urgently implemented at all levels.
A recent modeling study on infection control outcomes esti-
mated that half of anticipated XDR tuberculosis cases could be
prevented by applying a combination of available strategies in
developing countries [60]. Appropriate safety measures should
be implemented by clinical and laboratory staff when dealing
with biological samples from patients suspected of harboring
DR tuberculosis strains.
INFECTION CONTROL MEASURES AND
PATIENT RIGHTS
Balancing the rights of individual patients to have freedom of
movement and association vs protecting the rights of the
community at large to be protected from a dangerous path-
ogen is a difficult issue. During the severe acute respiratory
syndrome outbreak, immediate implementation of strict pa-
tient isolation measures helped to avert a global epidemic. The
situation with DR tuberculosis is more problematic because
millions of people are affected already, disease is often in-
dolent with slow progression over time, a prolonged course
of treatment is required (at least 2 years), and cure cannot
be guaranteed. Ensuring effective patient isolation during
the time of infectiousness (sputum smear positivity) sounds
like a logical intervention, but the scale of such an initiative
is overwhelming. The threat of long-term isolation from loved
ones and the huge economic consequences of having to visit and
support the patients would be a major disincentive to present
for diagnosis and treatment. Such a reaction may do more
harm than good, negatively impacting control of both drug-
susceptible and DR tuberculosis. The impact of various public
health interventions to limit ongoing transmission within
communities merits further discussion.
It is estimated that healthcare workers in South Africa have
a 6-fold higher risk for contracting MDR tuberculosis and
XDR tuberculosis compared with the general population [61].
WHO has published a policy on infection control that attempts
to address the needs of resource rich and resource-limited set-
tings [62]. This covers organizational activities (surveillance
and assessment at all levels of the health system), adminis-
trative controls (triage, cough etiquette, reduction of un-
necessary hospital stays, etc), environmental controls (natural
ventilation, mechanical ventilation, ultraviolet irradiation, and
health facility renovation), and personal protection (the use of
respirators for health staff and masks for patients and the
‘‘package of prevention and care for healthcare workers’’ [in-
cluding HIV prevention, antiretroviral therapy, and IPT for HIV-
positive healthcare workers]). The WHO policy on infection
control does not adequately distinguish between interventions
that can be readily applied in resource rich and resource poor
settings and not surprisingly in resource poor settings remains
poorly implemented. Increased collaboration between HIV and
tuberculosis screening and treatment programs will be essential as
a means of infection control in endemic settings in order to
mitigate the risk of transmission of tuberculosis, including in
clinical spaces where HIV-infected individuals are kept in close
contact with one another. Infection control management in
clinical settings can include measures such as integrated tuber-
culosis and HIV care, early diagnosis and linkage to treatment,
and appropriate ventilation and cough control, including triaging
patients with cough to a separate waiting area. In addition to
public health measures, early initiation of both antiretroviral
therapy and second-line anti-tuberculosis drugs is a critical factor
in survival of HIV-infected patients who are coinfected with
MDR tuberculosis or XDR tuberculosis.
DRUG-RESISTANT
TUBERCULOSISdPEDIATRIC ISSUES
Published data on DR tuberculosis in children is sparse, but in
general the pattern of drug resistance in children mirrors that
of emergence within the adult population [63]. A rising in-
cidence of DR tuberculosis has been reported in a longitudinal
surveillance study from South Africa, in which MDR tuber-
culosis among children newly diagnosed with tuberculosis in-
creased from 2.3% in the period 1994–1998 to 6.7% in the
period 2005–2007; increases in drug resistance among adult
cases in the same community were also tracked [58]. Successful
transmission of MDR M. tuberculosis strains demonstrates the
need to protect young and vulnerable children by limiting
their exposure to infectious cases and considering preventive
chemotherapy in the subgroup at highest risk of disease pro-
gression [64, 65]. The diagnosis of pediatric MDR tuberculosis
is often delayed due to reliance on the diagnosis of the adult
contact as a case of MDR tuberculosis, which depends on sputum
culture and drug susceptibility results. Diagnosis requires a high
index of suspicion because the culture yield in children makes
definitive microbiological confirmation difficult. Resistance
should be suspected if an index case has known resistant
tuberculosis, if the child shows initial improvement on anti-
tuberculosis treatment and then deteriorates, or if there is no
response to initial treatment. Acquired drug resistance in the
pediatric population is rarely reported; however, children with
M. tuberculosis–HIV coinfection could have high bacterial loads
as well as low drug levels, hence, they should be closely moni-
tored and adherence to treatment should be ensured. Table 4
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summarizes some of the principles related to prevention, di-
agnosis, and management of DR tuberculosis in children.
Definitive data regarding optimal therapy for pediatric DR
cases are lacking, but treatment cure rates .90% have been re-
ported for MDR cases [66], and children with XDR tuberculosis
have been successfully treated as well [67]. This demonstrates
that a rational approach to diagnosis and drug selection can lead
to good outcomes if adherence is maintained and side effects are
adequately managed [64, 66]. Most guidelines, although expert
opinion based, recommend regimens that include at least 4–5
active drugs, of which 1 should be an injectable agent and, if
possible, at least 2 should be bactericidal. In the absence of drug
susceptibility results, the child should be treated according to the
resistance profile of the most likely source case [64, 65]. The use
of high-dose INH (15 mg/kg) is likely to confer clinical benefit
with low or intermediate levels of INH resistance, which may be
suggested by genetic mutational analysis [68, 69]. However, INH
should not replace an active drug in the regimen, and combining
high-dose INH with ethionamide is probably a good strategy to
consider in the absence of sophisticated tests [68, 70].
Depending on the severity of disease and side effects experi-
enced, parenteral agents should be given for at least 4–6 months.
Although second-line anti-tuberculosis drugs have known
and potentially serious side effects, limited evidence in chil-
dren suggests that they tolerate these drugs at least as well as
adults [65]. There is general consensus that the benefits
of fluoroquinolones in the treatment of DR tuberculosis far
outweigh potential risks [64, 65]. Ciprofloxacin has the weakest
potency and should not be used if newer fluoroquinolones are
available. Amikacin is generally the injectable agent of choice
in children because it is less painful to inject intramuscularly
and is associated with fewer adverse effects than other agents.
However, prolonged use of any injectable agent is associated
with renal and hearing/vestibular toxicities, which may be de-
layed in onset. Hearing should be monitored during and for
at least 6 months after treatment completion because hearing
disability may have major consequences for language and
communication development [71]. Both ethionamide and
para-aminosalicylic acid (PAS) have been associated with
transient hypothyroidism, and thyroid replacement therapy
may be warranted during prolonged treatment, especially in
young children with active neurological development. Serine
analogues such as cycloserine/terizidone as well as INH and
some antiretroviral drugs can cause peripheral neuropathy;
routine pyridoxine supplementation is advised, especially in
HIV-infected children who frequently demonstrate persistently
low pyridoxine levels [72].
CONCLUSIONS
Multidrug-resistant tuberculosis and XDR tuberculosis are
spreading globally and now greatly complicate patient
Table 4. Issues Related to Drug-Resistant Tuberculosis in Children
Preventive therapy The best protection for vulnerable children is reduced exposure, which emphasizes the need for early
diagnosis of adult cases and implementation of effective infection control measures.
Children aged ,3 years are most vulnerable to progress to disease following exposure/infection.
High-dose INH preventive therapy (10–15 mg/kg) may offer some protection with low- or intermediate-level
INH resistance.
For INH or RIF monoresistance, either RIF (4 months) or INH (6–9 months) should provide adequate
protection.
As a general rule, the benefit-to-risk ratio for multidrug-resistant prophylaxis is likely to be highest in children
aged ,3 years. Using 2–3 oral drugs (6 months) to which the index strain is susceptible does provide
some protection.
Follow up of high-risk children is warranted for a period of at least 1 year.
Diagnosis Always take a detailed contact history.
Always collect at least 2–3 samples for culture and susceptibility testing before initiating treatment
following exposure to a drug-resistant source case.
Improved access to culture and molecular diagnostics should benefit children in whom microscopy
performs poorly.
Management Same principles apply as in adults, but children with minimal disease and low bacillary loads may be treated
for shorter durations (9–12 months of prescription drugs).
Always base treatment decisions on the drug susceptibility profile of the likely source case, and adjust as
needed should any of the child’s specimens yield a positive result.
Pay attention to dosage because pediatric formulations of second-line drugs are often not available.
Increased vigilance is required to monitor for adverse events (eg, transient hypothyroidism associated with
ethionamide or PAS treatment has increased relevance in an actively growing and developing child).
Ensure parental understanding of the need to complete a prolonged course of treatment and provide
ongoing support.
Abbreviations: INH, isoniazid; PAS, para-aminosalicylic acid; RIF, rifampicin.
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management within resource-poor national tuberculosis pro-
grams, reducing treatment efficacy and increasing the cost of
treatment to the extent that it could bankrupt healthcare systems
in tuberculosis-endemic areas. There is an urgent need for
program and laboratory infrastructure improvement and a dire
need for funders, donors, and governments to take these issues
seriously, especially in light of the current global economic re-
cession.
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